Novavax is no longer a pandemic manufacturer trying to sell its own Covid shot. The Gaithersburg firm has handed Nuvaxovid commercial leadership and the United States biologics license to Sanofi, and the equity now lives or dies on whether that partner converts a protein-based franchise and a Covid-flu combination program into royalties and named milestones. The second quarter booked $57 million of revenue against a year-ago period that included $202 million of one-time items. Strip those items and the story is a thinner, partner-funded operating company still waiting for the royalty line to show up.
The tension sits in the mix, not the headline decline. Product sales rose on Matrix-M adjuvant demand from Takeda and the Serum Institute, while Sanofi-related revenue was mostly transition reimbursements and amortization rather than a seasonal royalty engine. Combined research and selling costs after partner reimbursements fell by more than a third, which is the cost-cut working as designed. Cash and securities of $724 million still sit above $291 million of long-term debt. The counterargument is that the raised full-year framework still excludes Sanofi supply, royalties, and milestones, so the figure the market can actually underwrite remains a residual.
The next several quarters resolve a simple question about who actually owns the cash calendar. Does Sanofi start the combination late-stage study and produce a visible royalty season before Gavi settlement payments and leftover advance-purchase obligations consume the cash buffer, or does Novavax remain a well-funded options book whose partners keep the timetable? A $125 million combination-trial milestone sits behind a start date Sanofi has not locked.